1887

Abstract

Human infections with A/Jiangxi-Donghu/346/2013 (H10N8) virus have raised concerns about its pandemic potential. In order to develop a vaccine against this virus, the immunogenicity of its haemagglutinin protein was evaluated in mice. Using both whole-virion and recombinant subunit protein vaccines, we showed that two doses of either vaccine elicited neutralizing antibody responses. The protective efficacy of the vaccine-induced responses was assessed using a reverse-genetics-derived H10 reassortant virus on the A/Puerto Rico/8/34 (H1N1) backbone. The reassortant virus replicated efficiently in the respiratory tract of unvaccinated mice whereas vaccinated mice were completely protected from challenge, with no detectable viral load in the lower respiratory tract. Finally, the serum neutralizing antibody responses elicited by the H10 vaccines also exhibited cross-neutralizing activity against three heterologous wild-type H10 viruses. Collectively, these findings demonstrate that different vaccine platforms presenting the H10 haemagglutinin protein induce protective immunity.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000683
2017-02-01
2020-01-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/2/155.html?itemId=/content/journal/jgv/10.1099/jgv.0.000683&mimeType=html&fmt=ahah

References

  1. Parry J. H10N8 avian flu virus claims its first known human casualty. BMJ 2014;348:g1360 [CrossRef][PubMed]
    [Google Scholar]
  2. To KK, Tsang AK, Chan JF, Cheng VC, Chen H et al. Emergence in China of human disease due to avian influenza A(H10N8) – cause for concern?. J Infect 2014;68:205–215 [CrossRef][PubMed]
    [Google Scholar]
  3. World Health Organization Avian influenza A (H10N8). wpro.who.int. www.wpro.who.int/china/mediacentre/factsheets/h10n8/en/ accessed 13 August 2015
  4. Qi W, Su S, Xiao C, Zhou P, Li H et al. Antibodies against H10N8 avian influenza virus among animal workers in Guangdong Province before November 30, 2013, when the first human H10N8 case was recognized. BMC Med 2014;12:205–209 [CrossRef][PubMed]
    [Google Scholar]
  5. Zhang T, Bi Y, Tian H, Li X, Liu D et al. Human infection with influenza virus A(H10N8) from live poultry markets, China, 2014. Emerg Infect Dis 2014;20:2076–2079 [CrossRef][PubMed]
    [Google Scholar]
  6. Su S, Qi W, Zhou P, Xiao C, Yan Z et al. First evidence of H10N8 avian influenza virus infections among feral dogs in live poultry markets in Guangdong Province, China. Clin Infect Dis 2014;59:748–750 [CrossRef][PubMed]
    [Google Scholar]
  7. Vachieri SG, Xiong X, Collins PJ, Walker PA, Martin SR et al. Receptor binding by H10 influenza viruses. Nature 2014;511:475–477 [CrossRef][PubMed]
    [Google Scholar]
  8. Wang M, Zhang W, Qi J, Wang F, Zhou J et al. Structural basis for preferential avian receptor binding by the human-infecting H10N8 avian influenza virus. Nat Commun 2015;6:5600–5606 [CrossRef][PubMed]
    [Google Scholar]
  9. Zhang H, de Vries RP, Tzarum N, Zhu X, Yu W et al. A human-infecting H10N8 influenza virus retains a strong preference for avian-type receptors. Cell Host Microbe 2015;17:377–384 [CrossRef][PubMed]
    [Google Scholar]
  10. Yang H, Carney PJ, Chang JC, Villanueva JM, Stevens J. Structure and receptor binding preferences of recombinant hemagglutinins from avian and human H6 and H10 influenza A virus subtypes. J Virol 2015;89:4612–4623 [CrossRef][PubMed]
    [Google Scholar]
  11. Ramos I, Mansour M, Wohlbold TJ, Ermler ME, Hirsh A et al. Hemagglutinin receptor binding of a human isolate of influenza A(H10N8) virus. Emerg Infect Dis 2015;21:1197–1201 [CrossRef][PubMed]
    [Google Scholar]
  12. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci USA 2000;97:6108–6113 [CrossRef][PubMed]
    [Google Scholar]
  13. Huang YT, Turchek BM. Mink lung cells and mixed mink lung and A549 cells for rapid detection of influenza virus and other respiratory viruses. J Clin Microbiol 2000;38:422–423[PubMed]
    [Google Scholar]
  14. Schultz-Cherry S, Dybdahl-Sissoko N, McGregor M, Hinshaw VS. Mink lung epithelial cells: unique cell line that supports influenza A and B virus replication. J Clin Microbiol 1998;36:3718–3720[PubMed]
    [Google Scholar]
  15. Lau YF, Tang LH, Mccall AW, Ooi EE, Subbarao K. An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J Virol 2010;84:8639–8649 [CrossRef][PubMed]
    [Google Scholar]
  16. Deng G, Shi J, Wang J, Kong H, Cui P et al. Genetics, receptor binding, and virulence in mice of H10N8 influenza viruses isolated from ducks and chickens in live poultry markets in China. J Virol 2015;89:6506–6510 [CrossRef][PubMed]
    [Google Scholar]
  17. Tang LH, Lim JH, Kuah LF, Lau YF. Complete protection against lethal challenge of novel H7N9 virus with heterologous inactivated H7 vaccine in mice. Vaccine 2014;32:5375–5378 [CrossRef][PubMed]
    [Google Scholar]
  18. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ et al. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007;4:e59 [CrossRef][PubMed]
    [Google Scholar]
  19. Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL et al. Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 1998;8:683–691[PubMed][CrossRef]
    [Google Scholar]
  20. Lau YF, Tang LH, Ooi EE. A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 2009;27:1354–1364 [CrossRef][PubMed]
    [Google Scholar]
  21. Blanchfield K, Kamal RP, Tzeng W-P, Music N, Wilson JR et al. Recombinant influenza H7 hemagglutinins induce lower neutralizing antibody titers in mice than do seasonal hemagglutinins. Influenza Other Respir Viruses 2014;8:628–635 [CrossRef]
    [Google Scholar]
  22. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19:1732–1737[PubMed][CrossRef]
    [Google Scholar]
  23. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343–1351 [CrossRef][PubMed]
    [Google Scholar]
  24. Wohlbold TJ, Hirsh A, Krammer F. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13. Vaccine 2015;33:1102–1106 [CrossRef][PubMed]
    [Google Scholar]
  25. Lau YF, Tang LH, Ooi EE, Subbarao K. Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology 2010;406:80–87 [CrossRef][PubMed]
    [Google Scholar]
  26. Weldon WC, Wang BZ, Martin MP, Koutsonanos DG, Skountzou I et al. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 2010;5:e12466 [CrossRef][PubMed]
    [Google Scholar]
  27. Hernandez Alvarez B, Hartmann MD, Albrecht R, Lupas AN, Zeth K et al. A new expression system for protein crystallization using trimeric coiled-coil adaptors. Protein Eng Des Sel 2008;21:11–18 [CrossRef][PubMed]
    [Google Scholar]
  28. Lau YF, Santos C, Torres-Vélez FJ, Subbarao K. The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines. J Virol 2011;85:76–85 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000683
Loading
/content/journal/jgv/10.1099/jgv.0.000683
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error